Virtual Trials Help Develop Cancer Drugs

Virtual patient technology is an innovative biosimulation solution that aims at accelerating drug development. The technology is based on a computer-generated method of accurately predicting how individual patients or patient populations will respond to a compound. It combines computer models of human physiology, specific diseases, and the therapeutic impact of a compound.

The U.S. Patent and Trademark Office has granted patent approval to Optimata Ltd. (Ramat Gan, Israel) for the optimization of drug treatments for cancer patients. This is the first of a series of patent applications filed by Optimata for the company's platform technology, which uses mathematical modeling to optimize development of drugs and their use in treatment of diseases. The approved patent is entitled "System and Methods for Optimized Drug Delivery and Progression of Normal and Diseased Cells.”

Optimata technology forecasts the results of putative preclinical and clinical experiments allowing an unlimited number of virtual trials to be carried out on a large range of dosages, treatment schedules and patient population characteristics. This overcomes the time and cost limitations of trial-and-error methods currently used in drug development."We have already successfully used this technology in our collaborations with pharmaceutical and biotech companies” said Guy Malchi, president of the company.

Optimata was founded by Professor Zvia Azur, a biomathematician who utilizes methods of computer modeling for optimizing treatment protocols in cancer and pathogenic diseases.




Related Links:
Optimata